









Markets
/
Stocks
/
nasdaq-kpti
/

Karyopharm Therapeutics Inc

KPTI

6.260USD

+0.170+2.79%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

54.47MMarket Cap

LossP/E TTM



Karyopharm Therapeutics Inc

6.260

+0.170+2.79%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Karyopharm Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Karyopharm Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.40.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Karyopharm Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

95 / 159

Overall Ranking

258 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Karyopharm Therapeutics Inc Highlights

StrengthsRisks

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Overvalued

The company’s latest PE is -0.43, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 6.66M shares, increasing 14.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 559.62K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.400

Target Price

+144.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Karyopharm Therapeutics Inc is 7.73, ranking 98 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 44.04M, representing a year-over-year increase of 13.57%, while its net profit experienced a year-over-year increase of 3.29%.

Score

Industry at a Glance

Previous score

7.73

Change



Financials

5.46

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.80

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.42

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Karyopharm Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Karyopharm Therapeutics Inc is 7.08, ranking 100 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.43, which is -40.33% below the recent high of -0.25 and -501.62% above the recent low of -2.57.

Score

Industry at a Glance

Previous score

7.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Karyopharm Therapeutics Inc is 8.33, ranking 43 out of 159 in the Pharmaceuticals industry. The average price target is 15.00, with a high of 21.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.400

Target Price

+144.44%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Karyopharm Therapeutics Inc

KPTI

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Karyopharm Therapeutics Inc is 5.58, ranking 137 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.18 and the support level at 5.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.51

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.163

Sell

RSI(14)

43.422

Neutral

STOCH(KDJ)(9,3,3)

20.302

Neutral

ATR(14)

0.553

High Vlolatility

CCI(14)

-67.300

Neutral

Williams %R

70.943

Sell

TRIX(12,20)

-0.460

Sell

StochRSI(14)

50.692

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

6.302

Sell

MA10

6.528

Sell

MA20

6.786

Sell

MA50

6.705

Sell

MA100

6.349

Sell

MA200

5.742

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Karyopharm Therapeutics Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 36.38%, representing a quarter-over-quarter increase of 50.68%. The largest institutional shareholder is The Vanguard, holding a total of 559.62K shares, representing 3.06% of shares outstanding, with 49.59% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Investment Management, Inc.

2.30M

+228.71%

Opaleye Management Inc.

949.91K

J. Wood Capital Advisors LLC

784.80K

+71.30%

The Vanguard Group, Inc.

Star Investors

408.22K

-21.23%

Adage Capital Management, L.P.

421.32K

BlackRock Institutional Trust Company, N.A.

183.86K

-0.54%

Catalio Capital Management, LP

142.98K

-2.07%

Avidity Partners Management LP

134.57K

Marshall Wace LLP

128.45K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Karyopharm Therapeutics Inc is 2.66, ranking 124 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.